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ARTICLE
Pharmacodynamic Effects of Topical Omiganan in 
Patients With Mild to Moderate Atopic Dermatitis in a 
Randomized, Placebo-Controlled, Phase II Trial
Tessa Niemeyer-van der Kolk1,2, Hein van der Wall1,3, Geretta K. Hogendoorn1, Rianne Rijneveld1, Sascha Luijten1,  
Dirk C.J.G. van Alewijk4, Ellen H.A. van den Munckhof4, Marieke L. de Kam1, Gary L. Feiss5, Errol P. Prens6, Jacobus Burggraaf1,2,3, 
Robert Rissmann1,2,3,* and Martijn B.A. van Doorn1,6
Omiganan is an indolicidin analog with antimicrobial properties that could be beneficial for patients with atopic dermatitis. In 
this randomized, double-blind, placebo-controlled, phase II trial we explored the efficacy, pharmacodynamics, and safety of 
topical omiganan once daily in 36 patients with mild to moderate atomic dermatitis. Patients were randomized to apply topi-
cal omiganan 1%, omiganan 2.5%, or vehicle gel to one target lesion once daily for 28 consecutive days. Small but significant 
improvements in local objective SCORing Atopic Dematitis index and morning itch were observed in the omiganan 2.5% group 
compared with the vehicle gel group (−18.5%; 95% confidence interval, −32.9 to −1.0; P = 0.04; and −8.2; 95% confidence 
interval, −16.3 to −0.2; P = 0.05, respectively). A shift from lesional to nonlesional skin microbiota was observed in both 
omiganan treatment groups, in contrast to the vehicle group. Thus, treatment with topical omiganan improved dysbiosis in 
patients with mild to moderate atopic dermatitis, and small but statistically significant improvements in clinical scores were 
detected. Our findings warrant further exploration in future clinical trials.
Atopic dermatitis (AD) is a common skin disorder with a 
prevalence up to 3% in adults and up to 20% in children of 
the Western world.1 Patients with AD have xerotic erythem-
atous skin with oozing and crusting that typically occurs 
on the flexor sites of the body. Severe pruritus is the main 
and most bothersome symptom for most patients, and 
can lead to reduced quality of life and reduced quality of 
sleep.2 Current topical therapies for AD include bland emol-
lients in combination with anti-inflammatory agents, such as 
corticosteroids and calcineurin inhibitors. Side effects can 
be serious, including hypothalmic‒pituitary‒adrenal axis 
suppression with extensive topical corticosteroid therapy. 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  One of the hypothesized key factors involved in the 
pathogenesis of atopic dermatitis (AD), an inflammatory 
chronic skin disease, is colonization and infection of the 
skin with Staphylococcus aureus. Omiganan has dem-
onstrated antibacterial and anti-inflammatory properties 
and thus represents a promising new treatment for AD 
patients. Skin microbiome‒associated outcomes have the 
potential to function as biomarker in early-phase clinical 
AD trials.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  What are the effects on clinical efficacy, patient-re-
ported outcomes, pharmacodynamics, safety, and tolera-
bility of topical omiganan in patients with mild to moderate 
AD?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  Omiganan improved dysbiosis in patients with atopic 
dermatitis. Small but statistically significant clinical ef-
fects on the target lesion objective SCORing Atopic 
Dematitis index and morning itch were observed, render-
ing the clinical relevance debatable. Clinical improvement 
did not correlate with the improvement in dysbiosis.
HOW MIGHT THIS CHANGE CLINICAL PHARMA COL-
OGY OR TRANSLATIONAL SCIENCE?
✔  The results of this trial indicate that the role of S. au-
reus in the pathophysiology of AD appears to be minor in 
patients with mild to moderate disease severity. Although 
a clear proof of concept was not achieved, we demon-
strated proof of mechanism for the drug, i.e., improvement 
of dysbiosis, a clear sign of target engagement.
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Recently dupilumab, the first monoclonal anti‒interleukin-4 
antibody treatment for patients with moderate to severe 
AD, was registered, and it is likely that others will follow. 
However, for patients with mild disease, novel therapeutic 
agents with a favorable side effect profile are needed.
The pathophysiology of atopic AD is multifactorial and 
only partially understood. One of the factors involved in the 
pathogenesis is colonization and infection of the skin with 
Staphylococcus aureus, which can produce and secrete 
toxins and act as superantigens leading to inflamma-
tion.3 Colonization rates in a study of Park and colleagues 
showed that up to 90% of AD patients were colonized with 
this pathogen, compared with only 5–30% of the healthy 
subjects.4 A deficiency in antimicrobial peptides (AMPs), 
which are important in the host defense system of the skin, 
accounts for the susceptibility to this bacterium in AD pa-
tients.5 A dysregulated type 2 T-helper response in the skin 
leading to production of pro-inflammatory cytokines, such 
as interleukin (IL)-4 and IL-13, is most likely responsible for 
this AMP deficiency.6,7 Therefore, topical AMPs represent a 
promising new therapeutic option for patients with AD.
Omiganan is a novel, synthetic, cationic peptide and an 
analog of indolicidin, a short AMP of the cathelicidin family. 
It has demonstrated antimicrobial activity against a wide va-
riety of gram-positive and -negative bacteria and fungi.8–10 
Cationic peptides are also suggested to have immunomod-
ulatory roles in both pro- and anti-inflammatory pathways, 
depending on the context.11,12 The combination of anti-
bacterial and anti-inflammatory properties make omiganan 
a promising compound for the topical treatment of AD. 
Although omiganan has been investigated before in several 
other indications, e.g., acne vulgaris and rosacea, the cur-
rent trial is the to elucidate its effects in patients with AD.
In this study we aimed to explore the clinical efficacy, pa-
tient-reported outcomes, pharmacodynamics, safety, and 
tolerability of topical omiganan on one target lesion in pa-
tients with mild to moderate AD.
MATERIALS AND METHODS
Study design, randomization, and treatments
We conducted a randomized, double-blind, placebo-con-
trolled, single-center, phase 2 study to explore the clinical 
efficacy, patient-reported outcomes (PROs), pharmaco-
dynamics (PD), safety, and tolerability of omiganan in 36 
patients with mild to moderate AD. The Declaration of 
Helsinki was the guiding principle for trial execution, and 
the study was approved by the independent medical eth-
ics committee, Medisch Ethische Toetsingscommissie van 
de Stichting Beoordeling Ethiek Biomedisch Onderzoek 
(Assen, The Netherlands), before any trial procedure. All 
patients provided written informed consent before par-
ticipation. The study was conducted from June 2015 to 
November 2015 at the Centre for Human Drug Research, 
Leiden, The Netherlands. Eligible patients were random-
ized to apply either topical omiganan 1%, omiganan 2.5%, 
or vehicle gel (which served as placebo with an identical 
appearance), once daily (q.d.) for 28 consecutive days to 
one target lesion. This was done 1:1:1 in blocks of three ac-
cording to a randomization list with codes generated by an 
unblinded statistician. In addition to the active ingredient, 
omiganan pentahydrochloride, excipients of the compound 
are glycerine, hydroxyethyl cellulose, benzoic acid, sodium 
benzoate, and water. For safety reasons, only the predefined 
target lesion (one antecubital fossa) was treated in this first-
in-human study with drug/placebo but not with emollient. 
Study drug application was recorded using a validated mo-
bile-phone e-diary application. Subjects, study personnel, 
and investigators were blinded for the allocated treatment 
throughout the study. Emollients (unguentum leniens) were 
distributed for use once daily, but not to the target lesion. 
Patient visits were scheduled at days −14 (run-in period), 
0, 1, 3, 7, 14, 21, 28 (end of treatment), 35, and 42 (end of 
study). During the run-in period, patients applied emollients 
to the skin (not to the target lesion) and triamcinolone 0.1% 
ointment to the eczema lesions if needed, but not the target 
lesion. All study details are provided in the protocol and 
assessment schedule (refer to Supplementary Material 
S1 and S2).
Patients
Patients were included if: (i) AD was mild to moderate and 
(intermittently) present for >1 year; (ii) between the age of 18 
and 65 years; and (iii) willing to give written informed con-
sent. Inclusion criteria were an objective SCORing Atopic 
Dematitis (oSCORAD) index of 8–40, and an affected body 
surface area (BSA) of 5–15%. For PD assessments through-
out the study, all patients were required to have at least one 
target lesion (one antecubital fossa) affected by AD, a BSA 
of ≥0.5%, and a pruritus numeric rating scale (NRS) score of 
≥30 on a 0–100 scale. Washout periods for any type of AD 
medication were as follows: for cyclosporine, mycopheno-
late mofetil, and other systemic immunosuppressive drugs, 
4  weeks; phototherapy, 3  weeks; biologics, five half-lives 
of the drug; topical calcineurin inhibitors, 10 days; topical 
corticosteroids, 2 weeks; and any other topical medication 
(prescription or over the counter), 2  weeks. Patients with 
other clinically-significant (skin) conditions in the treatment 
area were excluded. Health status of included patients was 
verified by a detailed medical history, physical examina-
tion, vital signs, 12-lead electrocardiogram, and laboratory 
testing (including hepatic and renal panels, complete blood 
count, chemistry panel, virology, and urinalysis). Patients 
were evaluated for the four most prevalent fillagrin muta-
tions in Europe at screening (2282del4, R501x, S3247x, and 
R2447x).
Clinical efficacy, pharmacodynamic assessments, and 
PROs
One target lesion was assigned for treatment and PD as-
sessments in the trial. Another nontreated eczema lesion 
served as a control lesion for part of the PD measurements 
(off-target side). Clinical efficacy was assessed according 
to local oSCORAD index (percent BSA, erythema, edema/
papulation, oozing/crusting, excoriation, lichenification, and 
dryness) of the target lesion. Standardized images were 
obtained using a three-dimensional stereo-camera system 
(LifeViz QuantifiCare, Valbonne, France) for assessment of 
the target lesion size and roughness analysis. The skin bar-
rier status of lesional and nonlesional skin was assessed 
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by transepidermal water loss assessment (AquaFlux AF200 
System, Biox, London, UK). This was done under standard 
environmental conditions (temperature 22 ± 2°C, relative hu-
midity <60%) and patients were acclimatized under relaxed 
conditions for at least 15 minutes before measurement. All 
measurements were performed at each study visit. PROs 
consisted of NRS itch (0–100) and the 5-D itch scale.13,14 
The itch scores were divided into morning and evening itch 
to link the application time with efficacy outcomes.
Swab collection for microbiology
Patients were instructed not to wash or apply the study 
drug and keep the target lesion dry for at least 24 hours 
before each study visit. Skin swab samples were collected 
with sterile swabs that were dipped in NaCl Tween solu-
tion (REF 25-806-1PD, Puritan Sterile Polyester Tipped 
Applicator; Medtronic, Minneapolis, MN), before rubbing 
the tip of the swab firmly over 4  cm2 of the target lesion 
five times. Hereafter, the swab material was placed in a mi-
crotube (REF 72.694.105, Sarstedt, Numbrecht, Germany) 
containing 0.9% NaCl and 0.1% Tween 20. Analysis was 
performed as described by van den Munckhof et al.15
Microbiology analysis―S. aureus quantification
A singleplex quantitative polymerase chain reaction (qPCR), 
adapted from literature,16 targeting the nuc gene, was ap-
plied to quantify the S. aureus bacterial load. Quantification 
of bacterial load was done by comparing the results of the 
samples with the results of a standard curve with known 
concentrations. This standard curve was tested in paral-
lel to the samples in each experiment. Samples that were 
below the limit of quantification (LOQ) were used in the 
analysis as half the lower LOQ.
Microbiome analysis
DNA extraction was performed automatically (MagNA Pure 96 
DNA and Viral NA Large Volume Kit and Pathogen Universal 
500, Roche Diagnostics, Basel, Switzerland). We used an 
input volume of 500-μL sample and an elution volume of 
100 µL. After DNA extraction, variable regions V3 and V4 of 
the 16S rRNA gene were amplified using primers described by 
Klindworth et al.17: Bakt_341F (5′ CCTACGGGNGGCWGCAG 
3′) and Bakt_805R (5′ GACTACHVGGGTATCTAATCC 3′) with 
Illumina overhang adapter sequences added. The generated 
amplicons of around 460 base pairs were analyzed on a 
capillary system using a standard protocol, to confirm suc-
cessful amplification of a PCR fragment of the expected size. 
As a next step, PCR products were cleaned using Ampure 
XP beads (Beckman Coulter, Brea, CA) to remove primer 
dimers and small aspecific PCR products and the purified 
PCR products were quantified (Quant-iT PicoGreen dsDNA 
kit, Life Technologies, Carlsbad, CA), followed by serial dilu-
tion steps to reach the correct amount of input DNA. Index 
primers (Nextera XT Index kit, Illumina, San Diego, CA) were 
added by limited cycle PCR to the diluted PCR products. 
Before pooling, samples were normalized by using beads 
with maximum binding capacity and a sample preparation 
kit (Nextera XT).
The sequencing was performed on the Illumina MiSeq 
platform using an MiSeq v2 sequencing kit with 500 cycles 
(Illumina). De-multiplexed FASTQ files were generated as 
output and the sequences of the FASTQ files were ana-
lyzed using Metagenomics workflow of the MiSeq Reporter 
software (Illumina), resulting in a taxonomy percentage sum-
mary of the sequenced bacterial sample. To calculate the 
relative abundance of microorganisms at the genus level, 
the unclassified DNA was excluded, hence the sum of the 
percentages of the DNA of all microorganisms found was 
set at 100%. Furthermore, the microorganisms comprising 
<10% were excluded from the analysis.
Biopsy biomarkers. Skin punch biopsies (4  mm) were 
collected from lesional skin at day 0 (predose) and day 28 
and from nonlesional skin at day 0. Biopsies were placed in 
RNA later medium directly after harvest of the biopsy and 
stored and −80°C. The biopsies were analyzed at the DDL 
Laboratory (Rijswijk, The Netherlands). RNA extraction and 
real-time quantitative PCR analysis was performed relative 
to the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Because of limited material, 
a selection of protocol markers was made. The final set 
of markers was chosen based on disease involvement 
(IL-31, eotaxin, interferon-gamma (IFN-γ)) and expected 
investigational drug effects (IFN-α, IFN-γ, and IL-6).18
Safety and tolerability
Safety and tolerability end points were assessed by fre-
quency of treatment-emergent adverse events (TEAEs), 
serious adverse events (SAEs), discontinuations due to AEs 
or deaths, laboratory values (hematology, chemistry, co-
agulation, and urinalysis), vital signs, electrocardiographic 
parameters, and physical examination.
Treatment compliance and exposure
Compliance of study drug application was recorded using a 
mobile e-diary application, which entailed a notification and 
photo-capture function enabling the date and time docu-
mentation of each gel application.
Statistical methods
All calculations were performed using SAS for Windows 
version 9.4 (SAS Institute, Cary, NC). No formal power cal-
culation was performed given the exploratory character 
of this first-in-human study. Clinical efficacy and pharma-
codynamic end points were analyzed with a mixed-model 
analysis of variance using treatment, time, and treatment × 
time as fixed factors, and subject as random factor. 
Analyses were conducted in the clinical-evaluable popula-
tion. This population consisted of all subjects who applied 
the study medication for ≥21 days and completed the end-
of-treatment visit. The results per variable are estimates 
of the difference of the various contrasts and back- 
transformed estimates of the difference in percentage for 
log-transformed parameters, 95% confidence intervals (in 
percent for log-transformed parameters) and least-square 
means (back transformed for log-transformed parameters), 
and P-values for contrast. The analyses of the mRNA ex-
pressions in the biopsies incorporated normalization for 
the housekeeping gene GAPDH. Moreover, it incorporated 
the values from nonlesional skin to correct for the high 
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variability. Python version 3.5.2 software (Python Software 
Foundation, Wilmington, DE) was used for organization and 
visualization of the microbiome data.
RESULTS
Patients’ characteristics
Fifty-nine patients were screened, of whom 36 were en-
rolled in the study. All enrolled patients completed the 
study (Figure 1). Baseline characteristics were comparable 
between the treatment groups (Table 1). The overall mean 
BSA of the target lesion was 1.4% (±0.9).
Clinical efficacy
A reduction of the target lesion oSCORAD index was ob-
served in both active treatment groups compared with 
vehicle gel, mainly due to a reduction in percent BSA. This 
reduction was statistically significant for omiganan 2.5% 
(−18.5%; 95% confidence interval (CI), −32.9% to −1.0%), 
but not for omiganan 1% (−13.4%; 95% CI,  −28.4% to 
4.6%) (Figure 2a), which may indicate a dose-dependency. 
The reduction in the oSCORAD index in the omiganan 
2.5% group was accompanied with a trend in reduction of 
percent BSA of the target lesion (−0.31; 95% CI, −0.64 to 
0.03) (Figure  2b).
PROs
A significant decrease in score on the 0‒100 NRS itch scale 
was observed during the morning in the omiganan 2.5% 
group compared with the vehicle gel group (−8.2; 95% 
CI, −16.3 to −0.2), but not in the omiganan 1% group (−1.1; 
95%  CI,  −9.5 to 7.4). Itch during the evening slightly de-
creased in both active treatment groups. However, these 
decreases were not statistically significant (Figure  2c,d).
Exploratory pharmacodynamics
Skin barrier function as measured by transepidermal water 
loss assessment improved in all treatment groups (−4.5, 
−8.8, and −12 in the vehicle gel group, omiganan 1% group, 
and omiganan 2.5% group, respectively) (Figure  3a). The 
three-dimensional photo analysis revealed no significant 
changes in roughness of the skin surface (data not shown). 
Biomarkers demonstrated a high degree of variability in gen-
eral. At baseline, a significant difference between lesional and 
nonlesional mRNA expression in skin relative to GAPDH was 
Figure 1 Flowchart of the study. QD = qualified dose (once daily).
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observed for the markers eotaxin, IFN-γ, and IL-31 (Figure 
3b–d). There was no difference between lesional and non-
lesional skin for the markers IFN-α and IL-6. No significant 
reductions in biomarkers were observed for any of the treat-
ment groups. An example of the relative mRNA expression 
of eotaxin before and after treatment is shown in Figure  3e.
Microbiology and microbiome
No significant reductions in total bacterial load were ob-
served in the two active treatment groups, i.e., omiganan 
1% and omiganan 2.5%, compared with the vehicle gel 
group (data not shown). For the bacterial load information 
of S. aureus data by qPCR, a large proportion of samples 
showed results below the limit of quantification. There 
were no differences between treatment groups for the 
quantified samples. Microbiome data demonstrate a high 
degree of variability between patients in the presence and 
abundance of the genera. However, in general, the pres-
ence of the Staphylococcus genus dominated lesional 
skin compared with nonlesional skin (Figure  4). Individual 
data can be found in Supplementary Material S3. After 
both active treatments, Staphylococcus abundance de-
creased significantly from 64% to 37% for omiganan 1% 
(P = 0.05) and from 70% to 42% (P = 0.01) for omiganan 
2.5% compared with vehicle (Figures 4 and 5a), whereas 
abundance in the vehicle group remained stable. With the 
decrease of Staphylococcus abundance, the summary 
of the microbiome diversity (Shannon index) increased 
significantly up to a total change of 0.11 for omiganan 1% 
(P = 0.03) and 0.08 for omiganan 2.5% (P = 0.03 vs. vehi-
cle). At baseline, a moderate correlation was found between 
the target lesion oSCORAD index and Staphylococcus 
abundance (r = 0.409) and between the target lesion oS-
CORAD index and diversity index (r = 0.333). However, the 
decrease in the target lesion oSCORAD index as seen in 
both treatment groups did not correlate with the reduction 
in Staphylococcus abundance and increase in diversity 
(r = 0.182 and r = −0.096, respectively) (Figure 6)
Safety and tolerability
Eighteen of 36 patients (50%) had at least 1 TEAE. All 
TEAEs were of mild (n = 24) or moderate severity (n = 3), 
The most frequent TEAEs were headache, upper respira-
tory tract infection, and influenza-like illness. They were all 
self-limiting and were considered unlikely related (n = 28) to 
treatment. No local AEs were reported. No discontinuations 
due to adverse events occurred. Application did not result 
in any clinically significant changes in safety laboratory pa-
rameters or vital signs. No SAEs, discontinuations due to 
AEs, or deaths occurred.
Treatment compliance and exposure
Treatment compliance was high and comparable in all treat-
ment groups and ranged from 89% to 100%.19 The mean 
usage of study drug per day ranged from 1.2 to 1.3 mg/cm2 
in all treatment groups.











Female 9 (75) 10 (83) 8 (67) 27 (75)
Male 3 (25) 2 (17) 4 (33) 9 (25)
Age, years (SD) 25.0 (5.2) 25.1 (7.1) 24.7 (10.9) 24.9 (7.8)
Fitzpatrick skin type, n (%)
I 0 (0) 0 (0) 0 (0) 0 (0)
II 4 (33) 5 (42) 5 (42) 15 (42)
III 4 (33) 5 (42) 3 (25) 12 (33)
IV 1 (8) 1 (8) 2 (17) 4 (11)
V 2 (17) 0 (0) 1 (8) 3 (8)
VI 1 (8) 0 (0) 1 (8) 2 (6)
Years since diagnosis, mean (SD) 20.5 (9.4) 19.2 (10.9) 21.1 (12.2) 20.3 (10.6)
Exacerbations per year, mean (SD) 7.3 (6.9) 9.1 (6.4) 11.2 (9.8) 9.2 (7.8)
Subjects with filaggrin mutation, n (%) 0 (0%) 3 (25%) 4 (33%) 7 (19%)
BSA (%)―target lesion, mean (SD) 1.5 (0.9) 1.0 (0.5) 1.6 (1.1) 1.4 (0.9)
oSCORAD index―target lesion, mean (SD) 17.6 (7.5) 16.3 (4.5) 18.1 (8.4) 17.3 (6.8)
BSA (%)―all lesions, mean (SD) 9.1 (5.7) 7.0 (7.2) 8.9 (3.4) 8.3 (5.6)
oSCORAD index―total body, mean (SD) 18.4 (8.4) 18.9 (6.4) 17.8 (5.4) 18.4 (6.7)
Previous treatment with corticosteroids (USA classification), n (%)
Class IV corticosteroid 6 (50) 8 (67) 6 (50) 20 (56)
Class III corticosteroid 6 (50) 7 (58) 7 (58) 20 (56)
Class II corticosteroid 5 (42) 7 (58) 6 (50) 17 (47)
Class I corticosteroid 0 (0) 0 (0) 0 (0) 0 (0)
Calcineurin inhibitor 2 (17) 7 (58) 2 (17) 11 (31)
BSA, body surface area; oSCORAD, objective SCORing Atopic Dematitis; SD, standard deviation.
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DISCUSSION
This is the first randomized, controlled, double-blind clini-
cal trial exploring the clinical efficacy, pharmacodynamics, 
and safety of omiganan in patients with AD. Treatment with 
omiganan 2.5% resulted in a clinically small but statistically 
significant reduction in the target lesion oSCORAD index 
and morning itch after 28  days of treatment compared 
with treatment with vehicle gel. This reduction was mainly 
caused by a reduction in BSA. As proof of pharmacology, 
a shift from lesional to a nonlesional microbiome profile in 
terms of a reduction of Staphylococcus genus and increase 
in diversity was seen in both active treatment groups com-
pared with the vehicle gel group.
The shift in microbiome profile observed was predomi-
nantly driven by a reduction in Staphylococcus genus. This 
can be explained by the previously reported activity of omiga-
nan against this genus.8 The abundance of Staphylococcus is 
known to increase in skin affected by AD. Our study did show 
a moderate correlation between the clinical score (oSCORAD 
index) and the disturbed microbiome profile at baseline, which 
is in concordance with correlations of ≈0.50 described in other 
studies.20–22 The correlation of improvement of the oSCORAD 
index and the degree of dysbiosis would suggest a major 
role of the microbiome in the pathogenesis of AD. However, 
a decrease in abundance of Staphylococcus, or an increase 
in microbial diversity, did not correlate with oSCORAD index 
improvement in our study. In some patients, this relationship 
was even reversed. In contrast, in previous studies with other 
treatments, such as topical corticosteroids and emollients, a 
correlation of clinical improvement and Staphylococcus re-
duction and/or increase in diversity index was reported.20,22 A 
delay in clinical improvement after a recovery of the microbi-
ome or variable individual responsiveness of the microbiome 
in the small treatment group in our study may represent un-
derlying mechanisms prohibiting clear insight in the relation 
between the microbiome and clinical efficacy. It is also known 
that some individuals, by nature, have a greater abundance 
of Staphylococcus of up to 30% and/or a greater microbial 
diversity on the skin compared with others, although this does 
not appear to contribute to disease activity.23,24 An alternative 
explanation could be that recovering the microbiome in mild 
to moderate AD patients does not lead to an improvement 
of clinical symptoms, but the effect is the other way around, 
wherein reduction of inflammation leads to normalization of 
the microbiome. This notion is supported by the fact that there 
is no evidence for a beneficial effect of antimicrobial interven-
tions in noninfected AD, and the fact that the microbiome can 
recover with topical corticosteroids alone, which evidently lack 
antimicrobial properties.25 More studies are needed to provide 
Figure 2 Change from baseline in body surface area, objective SCORing Atopic Dematitis (oSCORAD) index and morning and evening 
itch in the omiganan 1% and 2.5% treatment groups compared with the vehicle gel group. Change from baseline graphs: delta least-
squares mean (LSM) data over time of clinical assessments for (a) body surface area (BSA) and oSCORAD (b) of the target lesion. In 
the lower panels, patient-reported outcomes are depicted, i.e., itch in the (c) morning and (d) evening.
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full insight in the relationship between the microbiome and in-
flammation in AD, as the outcomes of our study are not fully 
conclusive.
The clinical effects on the target lesion oSCORAD and 
affected BSA may be explained by the immunomodulatory 
effects of omiganan. Although there are no data available 
on omiganan, comprehensive data of immunomodulatory 
potential are available on another member of the catheli-
cidin family, namely LL-37, which is the only endogenous 
human cathelicidin. LL-37 has anti-inflammatory properties, 
including inhibition of AIM2 inflammasome formation and 
suppression of IFN-γ, tumor necrosis factor-α, IL-4, and 
IL-12.11,26,27 IFN-γ expression remained unchanged after 
treatment (data not shown), but the other pro-inflammatory 
markers were not included in this study. Moreover, LL-37 is 
involved in skin barrier homeostasis and presumably sup-
presses itch.28 On the contrary, LL-37 is also involved in 
several pro-inflammatory pathways when present in excess, 
such as in the downregulation of IL-10 and mast cell release 
of inflammatory mediators.29,30 In summary, there is evi-
dence from AMP family members that the clinical effects of 
omiganan can rely on immunomodulatory properties rather 
than antimicrobial properties, but more in vitro and in vivo 
studies with omiganan are needed to draw conclusions.
Microbiome as biomarker
In a previous literature review we described the potential of 
skin microbiome‒associated outcomes as a biomarker in 
Figure 3 Pharmacodynamic effects of topical omiganan in the omiganan 1%, omiganan 2.5%, and vehicle gel groups. (a) 
Transepidermal water loss (TEWL) over time is depicted, showing improvement in the treatment groups and the vehicle group. Relative 
mRNA expressions in skin punch biopsy of markers (b) interleukin-31, (c) eotaxin, and (d) interferon-γ in lesional vs. nonlesional skin 
in mild to moderate atopic dermatitis patients at baseline. Data presented as median with interquartile range. Statistical significance 
is as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, based on a paired t-test on log-transformed data. (e) Relative mRNA 
expression of eotaxin per treatment group before treatment of lesional skin (day 0) and after end of treatment of lesional skin (day 28) 
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early-phase clinical AD trials.31 Although the exact relation 
between the skin microbiome and AD pathophysiology re-
mains debatable based on this review, the implementation 
looks promising with respect to antimicrobial therapies.31 In 
an earlier longitudinal observation study of AD patients, the 
authors found no major dissimilarity and robust microbiome 
profiles over time for both lesion and nonlesion skin.15 In the 
current study we observed that the clear improvements in 
microbiome correlated only weakly with clinical response. 
Therefore, the microbiome may be considered a disease 
biomarker in AD to a lesser extent. For this part, because 
only a single AD lesion was treated and because high in-
terindividual microbiome variability was observed, a larger 
study with total body application is needed to explore the 
full potential. However, the microbiome in this study pro-
vided proof of pharmacology of topical omiganan in patients 
with mild to moderate atopic dermatitis by serving as a drug 
mechanistic biomarker when assessing target engagement.
Figure 4 Course of cutaneous microbiome after omiganan treatment over time. Relative Staphylococcus abundance over time in the 
(a) omiganan 1%, (b) omiganan 2.5%, and (c) vehicle groups. A reduction is seen in both active treatment groups, but not in the vehicle 
group. Nonlesional boxes are presented as control on the right side. Median values are shown in blue above the boxplots.
Figure 5 Omiganan improves dysbiosis of the target lesion. (a) Staphylococcus abundance and (b) diversity index from baseline to 
day 28 (end of treatment) per treatment group, with P-values of the differences calculated using a mixed model for data over time.
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Itch reduction not clinically meaningful
Although there was a small, statistically significant reduc-
tion in the morning itch with omiganan 2.5% treatment 
compared with vehicle, the minimal clinically important 
difference (MCID), which is the smallest patient-reported 
outcome change considered clinically meaningful,32 was 
not achieved. The mean reduction in NRS morning itch in 
the 2.5% treatment group was 8.2 (on a scale of 0–100), 
whereas the MCID for itch was represented by a 20‒30-
point reduction.33 The evening itch did not decrease 
significantly. When looking at the time of dose administra-
tion, most patients applied the gel in the morning (60%), 
which may explain why the effects on itch in the evening 
were less apparent. Itch reduction did not correlate with a 
reduction in IL-31 mRNA expression, a biomarker for itch, in 
the skin biopsies at end of treatment, which highlights the 
questionable clinical relevance of the observed reduction.34
Limitations
For safety reasons, only one target lesion was treated with 
the study drug, so the efficacy remains unknown with re-
gard to all lesions. When treating and trying to recover only 
one lesion in terms of inflammation and Staphylococcus 
reduction, auto-contamination of other lesions may occur, 
which may be relevant, assuming Staphylococcus plays a 
major role in the pathogenesis. However, our results indi-
cate a clear shift in microbiome profile with a reduction in 
Staphylococcus genus. It remains unclear whether this in-
cludes S. aureus or other Staphylococcus species, because 
analysis of species level was not feasible with our NGS de-
termination method. Unfortunately, the qPCR analysis was 
not able to perform quantitation in many samples, which 
precluded statistical analysis. Cultures for comparison with 
our NGS method were not performed in this study. Another 
limitation concerns the scoring of itch of the target lesion 
only. It may be difficult for patients to discern the itch from 
the target lesion from the itch related to other AD lesions 
and this may have influenced the scoring. Furthermore, 
study groups were relatively small for making definite con-
clusions about efficacy, and the clinical relevance of the 
decrease in target lesion oSCORAD and morning itch is 
therefore debatable.
In conclusion, in patients with mild to moderate AD, the 
topical administration of omiganan q.d. to a limited treat-
ment area for up to 28  days is safe and well tolerated. 
Pharmacologic activity in terms of a significant reduction 
in the oSCORAD of the predefined target lesion and the 
patient-reported itch was observed with the highest dose 
of 2.5%. However, because these reductions were small, 
the clinical relevance of both is debatable. The microbiome 
showed a significant shift from a lesional to nonlesional 
skin profile with both active treatments, indication low cor-
relations with clinical improvement. Future studies with 
optimization of the treatment regimen, i.e., dose (explora-
tion of more concentrations), frequency (b.i.d. instead of 
q.d.), and other subindications (such as infected AD), are 
needed to determine the true potential of omiganan in pa-
tients with AD.
Figure 6 Correlation analysis of target lesion objective SCORing Atopic Dematitis (oSCORAD) index and Staphylococcus abundance. 
Correlations are shown between the (a) local target lesion oSCORAD index and Staphylococcus abundance in the microbiome and for 
the (b) target lesion oSCORAD and diversity index. (c,d) Delta correlations.
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Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
cts-journal.com).
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